News about Global Pharma

FDA Approves First Mesenchymal Stromal Cell Therapy 'RYONCIL'

The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children two months and older.

Global Pharma | 17/01/2025 | By Manvi |  711

Samsung Biologics Highlights 2025 Outlook at J.P. Morgan Healthcare Conference

Samsung Biologics announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.

Global Pharma | 17/01/2025 | By Manvi |  915

Alembic Pharmaceuticals Announces USFDA Final Approval for Brexpiprazole Tablets

Alembic Pharmaceuticals has received USFDA final approval for its ANDA of Brexpiprazole Tablets in multiple strengths, a therapeutic equivalent to Otsuka's Rexulti, used for major depressive disorder and schizophrenia.

Global Pharma | 17/01/2025 | By Manvi |  306

Innovent and ASK Pharma Announce NMPA Approval of Limertinib for Lung Cancer

Innovent Biologics and Jiangsu Aosaikang Pharmaceutical announced that China's NMPA has approved the New Drug Application (NDA) of limertinib for treating adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC).

Global Pharma | 17/01/2025 | By Manvi |  351

Avicanna and Vectura Fertin Pharma Form Joint Committee to Advance Medical Cannabis Research in Canada

Avicanna and Vectura Fertin Pharma are collaborating to establish a joint Scientific and Medical Affairs Committee focused on improving the understanding of medical cannabis access and applications in Canada.

Global Pharma | 17/01/2025 | By Abha |  556

Biofidelity and CellCarta Announce Partnership to Enhance NSCLC Clinical Trials with Aspyre Lung

Aspyre Lung simplifies the detection of established non-small cell lung cancer (NSCLC) biomarkers by analysing both DNA and RNA from tissue and blood using a streamlined four-step workflow.

Global Pharma | 17/01/2025 | By Abha |  410

Sun Pharma to Acquire Canada-based Clinical-stage Biotechnology Company Antibe Therapeutics

Sun Pharmaceutical Industries Ltd. is set to acquire Canada-based Antibe Therapeutics, a clinical-stage biotech firm focused on pain and inflammation drugs, through its subsidiary TARO Pharmaceuticals. The indicative period for completion of the acquisition is before March 7, 2025.

Global Pharma | 16/01/2025 | By Manvi |  881

ErlySign Secures INR 16 Crore in Pre-Series A Funding from Investor Ashish Kacholia

The investment, advised by DerivativeSaint—a boutique private equity and venture capital advisory firm—marks a pivotal moment for CURO Biosciences.

Global Pharma | 16/01/2025 | By Aishwarya |  644

Alembic Pharmaceuticals Gets USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Depakote Sprinkle Capsules, 125 mg, of AbbVie Inc.

Global Pharma | 16/01/2025 | By Aishwarya |  453

Piramal Pharma to Operate its Digwal Facility on Biomass Briquettes to Promote Sustainability

This achievement marks a substantial step toward Piramal's sustainability goal to reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 42 percent by 2030.

Global Pharma | 16/01/2025 | By Aishwarya |  1104